Langsung dari ASCO 2024 | Ascentage Pharma Merilis Data Terbaru Inhibitor FAK/ALK/ROS1 APG-2449 pada Pasien NSCLC oleh Investing.com
Ascentage Pharma continues to push the boundaries of cancer treatment with their innovative drug candidate, APG-2449, a FAK/ALK/ROS1 tyrosine kinase inhibitor. The latest data presented at the ASCO Annual Meeting demonstrates promising efficacy in patients with non-small-cell lung cancer (NSCLC), particularly in those who are resistant to second-generation ALK inhibitors. Biomarker analysis showed correlations between … Baca Selengkapnya